ZTS Zoetis Inc
Company Analysis
Latest News
🔴 Zoetis is trading 4.1% down today after lower 2026 adjusted EPS guidance
Zoetis is trading 4.1% down at $72.27, despite broader U.S. indexes trading higher, after the company lowered 2026 adjusted EPS guidance. - Following the...
Zoetis Slashes Its 2026 Outlook for the Second Time — Can the Pet-Health Giant Stop the Bleeding?
Shares of Zoetis cratered 6.3% to $72.38 on August 7, bucking a broadly rising market, after the world's largest animal-health company cut its full-year...
🔴 Zoetis is trading 6.33% down today after cutting 2026 revenue and EPS guidance
Zoetis is trading 6.33% down at $72.38 after investors reacted to its August 6 earnings release and sharply reduced 2026 outlook. - Second-quarter revenue was...
Zoetis Appoints James Saccaro as Executive Vice President, CFO and COO
Zoetis announced the appointment of James Saccaro to the newly created role of Executive Vice President, Chief Financial Officer and Chief Operating Officer,...
🟢 Zoetis is trading 4.03% up today despite reduced 2026 EPS guidance
Zoetis is trading 4.03% up at $77.39, with the gain appearing partly supported by healthcare-sector strength despite mixed second-quarter results and reduced...
Zoetis second quarter revenue of $2.47B misses estimates as company cuts full-year 2026 guidance on companion animal weakness.
Zoetis reported flat second quarter revenue of $2.47 billion, missing consensus estimates of $2.51 billion. Adjusted EPS came in at $1.87, slightly ahead of...
Zoetis Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
For the second quarter of 2026, Zoetis is expected to report consensus revenue of $2.51 billion (+0.4% YoY) and adjusted EPS of $1.84 (+4.5% YoY), while the...
Investor Michael Burry Increases Stake in Zoetis Ahead of Earnings Report
Michael Burry increased his position in Zoetis, an animal health company. This move precedes Zoetis' early August earnings report. Zoetis stock saw modest...
Zoetis faces fraud lawsuit deadline, following Librela sales and stock plunge
Investors face a July 27, 2026, court-appointed deadline to apply as lead plaintiff in a securities fraud class-action lawsuit against Zoetis Inc. The...
Zoetis Launches Portela in Canada and EU, Providing 3-Month Feline OA Relief
Zoetis Inc. launched Portela (relfovetmab) commercially in Canada and the European Union. This product is the first long-acting anti-nerve growth factor (NGF)...
Zoetis' $160M Acquisition of Neogen's Genomics Arm Faces In-Depth Australian Antitrust Review
Australian regulators initiated a detailed Phase 2 review of Zoetis Inc.'s proposed $160 million acquisition. The acquisition targets Neogen Corp.'s animal...
Zoetis Drops to Russell Midcap Index, Following 50% Annual Stock Slump
Zoetis Inc. moved to the Russell Midcap Index in late June 2026. The company was previously listed in the Russell Top 200 and 1000 indexes. This...
Zoetis Hits 52-Week Low, Driven by Barclays 37% Target Cut
Barclays lowered its price target for Zoetis (ZTS) to $85 from $136. This 37% reduction follows a challenging first quarter for the animal health firm. The...
🟢 ZTS is trading 57.7% up today following recent selloff and ongoing securities litigation
ZTS is trading at $122.70 (+57.65%) after hours on June 25, 2026, following a period of intense volatility and a sharp recent selloff. * The stock had...
Zoetis Sued for Fraud After 21.5% Stock Drop, Lowered Profit Outlook
Pomerantz LLP filed a class-action lawsuit against Zoetis Inc. on June 24, 2026. The suit alleges securities fraud and unlawful business practices. The...
Zoetis Sued for Misleading Investors, Citing Librela Safety and Market Loss
The Schall Law Firm and DJS Law Group filed a securities class action lawsuit against Zoetis Inc. The legal action covers the period between January 14, 2025,...
🟢 Zoetis Inc is trading 4% up today in relief rebound from recent litigation-driven pressure
Zoetis Inc is trading 4% up at $81.98 in a relief rebound following recent pressure tied to litigation headlines and weakness in prior sessions. • The stock...
Zoetis Downgraded by Argus Amid Competitive Pressures
Argus Research downgraded Zoetis Inc. to 'Hold' from 'Buy'. The firm cited increased competition, shifting animal health market demand, and margin...
Zoetis Sued Over Misleading Pet Drug Claims, Following 21.5% Stock Drop
Labaton Keller Sucharow LLP filed a securities class action lawsuit against Zoetis Inc. and its executives. The suit alleges the company made false and...
Zoetis first quarter 2026 earnings miss estimates as U.S. pet care sales decline 11%
Zoetis reported first quarter 2026 revenue of $2.3 billion, up 3% year-over-year, and adjusted EPS of $1.53, missing analyst estimates of $1.61. The...